LENZ Therapeutics Enters Exclusive Licensing and Commercialization Agreement with Arrotex Pharma for VIZZ in Australia and New Zealand

Lenz Therapeutics（NasdaqLENZ Therapeutics has entered into an exclusive licensing and commercialization agreement with Arotex Pharma, granting the latter exclusive rights to register and market 1.44% VIZZ (aceclidine ophthalmic solution) in Australia and New Zealand.

Key information is as follows:

The translated content is generated by third-party software.

Disclaimer: The market involves risks, and investment should be approached with caution. This article was generated by an AI large language model based on publicly available information and does not represent the views of Sina Finance. All information, data, and charts contained herein are for reference only and do not constitute any form of investment advice or basis for decision-making; relevant information shall be subject to actual announcements. For inquiries, please contact: biz@staff.sina.com.cn.

Responsible Editor: Xiaolang Express